Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Остеопонтин, CD55: прогностические факторы риска при раке молочной железы
Остеопонтин, CD55: прогностические факторы риска при раке молочной железы
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В настоящее время увеличивается количество показателей, рассматривающихся в качестве потенциальных маркеров рака молочной железы, отражая достижения и находки в области изучения механизмов регуляции пролиферации и дифференцировки опухолевых клеток. Это относится и к таким маркерам, как CD55 и остеопонтин. Повышенная экспрессия остеопонтина в опухолях молочной железы свидетельствует об инвазивном потенциале опухолевой ткани, а степень экспрессии остеопонтина увеличивается с повышением степени злокачественности опухоли. Многие исследователи высказывают предположение, что наличие даже небольшого количества клеток с экспрессией СD55 в ткани опухоли обусловливает неблагоприятный прогноз. Данная работа посвящена изучению значения CD55 и остеопонтина в качестве прогностических онкомаркеров рака молочной железы.
Ключевые слова: рак молочной железы, онкомаркеры, CD55, остеопонтин.
Key words: breast cancer, oncomarkers, CD55, osteopontin (OPN).
Ключевые слова: рак молочной железы, онкомаркеры, CD55, остеопонтин.
________________________________________________
Key words: breast cancer, oncomarkers, CD55, osteopontin (OPN).
Полный текст
Список литературы
1. Ashkar S, Weber GF, Panoutsakopoulou V et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000; 287 (5454): 860–4.
2. Bellovici M, Ketelslegers JM, Colson A et al. Smoking is associated with increased levels of osteopontin in type 2 diabetic patients: preliminary results. Diabetes Metab 2006; 32 (5): 485–6.
3. Cho HJ, Cho HJ, Kim HS. Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep 2009; 11 (3): 206–13.
4. Coppola DM, White LE. Visual experience promotes the isotropic representation of orientation preference. Vis Neurosci 2004; 21 (1): 39–51.
5. Denhardt DT, Burger EH, Kazanecki C et al. Osteopontin-deficient bone cells are defective in their ability to produce NO in response to pulsatile fluid flow. Biochem Biophys Res Commun 2001; 288 (2): 448–53.
6. Faneyte IF, Kristel PM, Maliepaard M et al. Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res 2002; 8 (4): 1068–74.
7. Franzen A, Heinegard D. Isolation and characterisation of two sialoproteins present only in bone calcified matrix. Biochemical J 1985; 232: 715–24.
8. Furger KA, Menon RK, Tuck AB et al. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001; 1 (5): 621–32.
9. Gómez-Ambrosi J, Catalán V, Ramírez B et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 2007; 92 (9): 3719–27.
10. Hijiya N, Setoguchi M, Higuchi Y et al. Cloning and characterization of the human osteopontine gene and its promoter. Biochemical J 1994; 303: 255–62.
11. Ibrahim T, Leong I, Sanchez-Sweatman O et al. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin & Experim Metastasis 2000; 18 (3): 253–60.
12. Ikeda J, Morii E, Liu Y et al. Prognostic significance of CD55 expression in breast cancer. Clin Cancer Res 2008; 14 (15): 4780–6.
13. Kapoor S. Inhibition of osteopontin dependent carcinogenesis. J Cancer Res Clin Oncol 2008; 134 (8): 927–8.
14. Klusonová P, Reháková L, Borchert G et al. Chronic intermittent hypoxia induces 11-beta-hydroxysteroid dehydrogenase in rat heart. Endocrinol 2009; 150 (9): 4270–7.
15. Madjd Z, Durrant LG, Bradley R et al. Loss of CD55 is associated with aggressive breast tumors. Clin Cancer Res 2004; 15: 2797–803.
16. Mazzali M, Hughes J, Dantas M et al. Effects of cyclosporine in osteopontin null mice. Kidney Int 2002; 62 (1): 78–85.
17. Patani N, Jouhra F, Jiang W et al. Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res 2008; 28 (6): 4105–10.
18. Patarca R, Freeman G, Singh R et al. Structural and functional studies of the early T-lymphocyte activation-1 (Eta-1) gene. J of Experim Med 1989; 170: 145–61.
19. Ribeiro-Silva A, Oliveira da Costa JP et al. Osteopontin expression according to molecular profile of invasive breast cancer: a clinicopathological and immunohistochemical study. Int J Biol Markers 2008; 23 (3): 154–60.
20. Rushmere NK, Knowlden JM, Gee JM et al. Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. Intern J Cancer 2004; 108 (6): 930–6.
21. Trueblood NA, Inscore PR, Brenner D et al. Biphasic temporal pattern in exercise capacity after myocardial infarction in the rat: relationship to left ventricular remodeling. Am J Physiol Heart Circ Physiol 2005; 288 (1): 244–9.
22. Vetrone SA, Montecino-Rodrigues E, Kudryashova E et al. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest 2009; 119 (6): 1583–94.
23. Wang X, Chao L, Ma G et al. Primary breast carcinoma: association of mammographic calcifications with osteopontin expression. Radiology 2010; 254 (1): 69–78.
24. Xu JX, Morii E, Liu Y et al. High tolerance to apoptotic stimuli induced by serum depletion and ceramide in side-population cells: high expression of CD55 as a novel character for side-population. Experim Cell Research 2007; 313 (9): 1877–85.
2. Bellovici M, Ketelslegers JM, Colson A et al. Smoking is associated with increased levels of osteopontin in type 2 diabetic patients: preliminary results. Diabetes Metab 2006; 32 (5): 485–6.
3. Cho HJ, Cho HJ, Kim HS. Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep 2009; 11 (3): 206–13.
4. Coppola DM, White LE. Visual experience promotes the isotropic representation of orientation preference. Vis Neurosci 2004; 21 (1): 39–51.
5. Denhardt DT, Burger EH, Kazanecki C et al. Osteopontin-deficient bone cells are defective in their ability to produce NO in response to pulsatile fluid flow. Biochem Biophys Res Commun 2001; 288 (2): 448–53.
6. Faneyte IF, Kristel PM, Maliepaard M et al. Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res 2002; 8 (4): 1068–74.
7. Franzen A, Heinegard D. Isolation and characterisation of two sialoproteins present only in bone calcified matrix. Biochemical J 1985; 232: 715–24.
8. Furger KA, Menon RK, Tuck AB et al. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001; 1 (5): 621–32.
9. Gómez-Ambrosi J, Catalán V, Ramírez B et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 2007; 92 (9): 3719–27.
10. Hijiya N, Setoguchi M, Higuchi Y et al. Cloning and characterization of the human osteopontine gene and its promoter. Biochemical J 1994; 303: 255–62.
11. Ibrahim T, Leong I, Sanchez-Sweatman O et al. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin & Experim Metastasis 2000; 18 (3): 253–60.
12. Ikeda J, Morii E, Liu Y et al. Prognostic significance of CD55 expression in breast cancer. Clin Cancer Res 2008; 14 (15): 4780–6.
13. Kapoor S. Inhibition of osteopontin dependent carcinogenesis. J Cancer Res Clin Oncol 2008; 134 (8): 927–8.
14. Klusonová P, Reháková L, Borchert G et al. Chronic intermittent hypoxia induces 11-beta-hydroxysteroid dehydrogenase in rat heart. Endocrinol 2009; 150 (9): 4270–7.
15. Madjd Z, Durrant LG, Bradley R et al. Loss of CD55 is associated with aggressive breast tumors. Clin Cancer Res 2004; 15: 2797–803.
16. Mazzali M, Hughes J, Dantas M et al. Effects of cyclosporine in osteopontin null mice. Kidney Int 2002; 62 (1): 78–85.
17. Patani N, Jouhra F, Jiang W et al. Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res 2008; 28 (6): 4105–10.
18. Patarca R, Freeman G, Singh R et al. Structural and functional studies of the early T-lymphocyte activation-1 (Eta-1) gene. J of Experim Med 1989; 170: 145–61.
19. Ribeiro-Silva A, Oliveira da Costa JP et al. Osteopontin expression according to molecular profile of invasive breast cancer: a clinicopathological and immunohistochemical study. Int J Biol Markers 2008; 23 (3): 154–60.
20. Rushmere NK, Knowlden JM, Gee JM et al. Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. Intern J Cancer 2004; 108 (6): 930–6.
21. Trueblood NA, Inscore PR, Brenner D et al. Biphasic temporal pattern in exercise capacity after myocardial infarction in the rat: relationship to left ventricular remodeling. Am J Physiol Heart Circ Physiol 2005; 288 (1): 244–9.
22. Vetrone SA, Montecino-Rodrigues E, Kudryashova E et al. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest 2009; 119 (6): 1583–94.
23. Wang X, Chao L, Ma G et al. Primary breast carcinoma: association of mammographic calcifications with osteopontin expression. Radiology 2010; 254 (1): 69–78.
24. Xu JX, Morii E, Liu Y et al. High tolerance to apoptotic stimuli induced by serum depletion and ceramide in side-population cells: high expression of CD55 as a novel character for side-population. Experim Cell Research 2007; 313 (9): 1877–85.
Авторы
Ж.М.Гузиева1, И.В.Поддубная1, Я.В.Вишневская2, Н.П.Макаренко1, К.В.Сытенкова1
1 Кафедра онкологии ГБОУ ДПО РМАПО Минздравсоцразвития РФ, Москва
2 РОНЦ им. Н.Н.Блохина РАМН, Москва
1 Russian Medical Academy for Postgraduate Training, Chair of Oncology, Moscow
2 N.N.Blokhin Russian Cancer Research Center of RAMS, Moscow
1 Кафедра онкологии ГБОУ ДПО РМАПО Минздравсоцразвития РФ, Москва
2 РОНЦ им. Н.Н.Блохина РАМН, Москва
________________________________________________
1 Russian Medical Academy for Postgraduate Training, Chair of Oncology, Moscow
2 N.N.Blokhin Russian Cancer Research Center of RAMS, Moscow
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.